Hôpital Erasme - ULB
" Background: In the Covid-19 pandemic context, all healthcare teams face clinical, organizational and technical challenges given the contagion, severity and mortality characteristics of the disease. Methods: A cross-sectional multicentric study (NCT04344145) aiming to compare levels of burnout, emotional distress and needs between frontline Covid-19 and non-Covid-19 healthcare workers has been conducted between April 16th and May 25th. Physicians, nurses and physiotherapists were recruited from emergency care units and Covid-19 care units (target group) and from non-Covid-19 care units (control group) from Erasme Hospital, Jolimont-Lobbes Hospital and Mons-Warquignies Hospital (N = 603). Participants completed self-reported questionnaires and scales. A mixed-mode data collection was carried out, either in paper form or web-based form. Assessment provided socio-demographic characteristics and professional information. It also measured professional fulfillment and...

Read more: Julien Tiete, Dr

Erasme Hopital
" Nutritional assessment and support for optimal rehabilitation following COVID 19 critical illness "
Funding: NA
Contact: NA

CUB-Erasme
" "Background: There are no currently approved therapeutics for COVID-19 disease. This disease causes significant morbidity and mortality. Main Objectives: The overall objective of the study is to evaluate the clinical efficacy and safety of different investigational therapeutics relative to the control arm in patients hospitalized with COVID-19 patients. The primary endpoint is subject clinical status (on a 7-point ordinal scale) on Day 15. The secondary objectives are to evaluate clinical, and virological efficacy, and safety of different investigational therapeutics as compared to the control arm. Study design: This is a prospective, worldwide, adaptive, randomized, controlled, open study comparing 4 different treatments for COVID-19. The protocol is based on the WHO Master protocol of the Solidarity trial. The DisCoVeRy protocol previews more data collection and lower dosage regimens of Hydroxychloroquine than in the SOLIDARITY trial. Randomization is performed by...

Read more: Maya Hites, Associate Professor

CUB-Erasme
" "a. Background Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a new coronavirus SARS CoV-2, responsible for the current pandemic, causing a lot of morbidity and mortality. Most people with COVID-19 develop mild respiratory illness (stage I). However, in a sub-group of patients (+/- 15%) there are increasing respiratory symptoms and persistent fever (stage II). Patients may develop acute lung injury (hypoxia, and bilateral opacities on chest computed tomography (CT-scan)), requiring hospitalisation. A further 5% of patients develop stage III disease, requiring admission to the intensive care unit (ICU) due to acute respiratory distress syndrome (ARDS), sepsis and septic shock, and multi-organ failure. As patients progress from stage I to stage III, there are increasing signs of systemic hyper-inflammatory response, reflected by high levels of cytokines, C-reactive protein (CRP), ferritin, and lymphopenia. Different viral, bacterial, and...

Read more: Maya Hites, Associate Professor

Bordet Institute
" On April 11th, 2020, four patients hospitalized for more than 7 days developed fever some of them respiratory symptoms compatible with Covid-19 infection and were detected positive for SARS-CoV2. A 5th patient was also detected positive , had minor symptoms and was admitted 2 days earlier for collecting PBSC As a consequence of this mini-outbreak a screening of healthcare workers at this Unit revealed 2 staff members positive for SARS-CoV2. Severe acute respiratory distress syndrome Coronavirus 2(SARS-CoV2), causing Covid19 pandemic is rapidly spreading from person-to-person, via respiratory droplets, direct contact with mucous membranes or indirect contact through touching infected surfaces and then touching own eyes, nose or mouth. Airborne transmission after generated aerosols (intubation, bronchoscopy, tracheal aspiration,…) have been previously reported for other Coronaviruses(SARS-CoV1, MERS) and has been postulated for SARS-Cov2. In critical units such as the...

Read more: Mickael Aoun, Infectiologist

UCLouvain/Cliniques universitaires Saint-Luc 
" COVID-19 pandemic has an important impact on the health care provided by the anesthesiologists. Different societies of anesthesiology have provided guidelines and recommendations on how to manage patients who have been tested positive for COVID-19 or suspected to be infected. It is therefore important to know whether these guidelines have been implemented or were possible to be implemented. Otherwise patients who are presenting COVID-19 often show pulmonary complications. The airway management and the ventilation management of these patients can be therefore challenging and can possibly influence their outcome. It is thus important to obtain a large database with information about the characteristics of these patients, how these patients have been managed and their in-hospital outcome. Information regarding the correct implementation of guidelines is as well necessary for future guidance of health care providers. "
Funding: None
Contact...

Read more: Mona Momeni, MD, PhD

ULB/ERASME
" Severe COVID-19 patients have a greater risk of long-term health issues and sometimes develop permanent lung damage or fibrosis needing a long treatment to enhance their quality of life. The project aims to better quantify the breathing parameters of a patient to assess his revalidation evolution. A 3D image acquisition based system, provides contacless and non invasive measure. The system can be used as a complementary diagnosis tools as well for a quantitative follow up. "
Funding: So far the project is supported by volunteering inside the ULB/Laboratory of Image Synthesis and Analysis (LISA) and the Erasme Hospital
Contact: Olivier Debeir < This email address is being protected from spambots. You need JavaScript enabled to view it.> & Olivier Van Hove < This email address is being protected from spambots. You need JavaScript enabled to view it.>

Erasme Hospital
" Precise the frequency of thrombosis events in COVID19 patients "
Funding: No need
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.

ULiège, CHU - Royal Academy of Medicine of Belgium
" Nous faisons face à une pandémie d'infection COVID-19. Ce virus pathogène est source de complications pulmonaires aggravant fortement le pronostic de nos patients. De nos jours, tant les mécanismes physiopathologiques en cause que les marqueurs de sévérité de l'atteinte restent indéterminés. Il apparaît donc comme urgent de pouvoir identifier des marqueurs diagnostiques, pronostiques et prédictifs pour nos patients. Dans ce contexte, plusieurs voies rapidement explorables nous apparaissent comme critiques. Le but final de cette étude est de contribuer à une prise en charge plus ciblée des patients porteurs d'une infection au SRAS-Cov-2. "
Funding: Fonds Léon Frederic
Publication References: Dix publications représentatives : 1) Prevention of murine radiogenic thymic lymphomas by tumor necrosis factor or by marrow grafting. HUMBLET C, GREIMERS R, DELVENNE P, DEMAN J, BONIVER J, DEFRESNE MP. J Natl Cancer Inst 88 (1996), 824-831. IF...

Read more: Ph. DELVENNE, FNRS Research Director / Chef de service Anatomie pathologique - J. GUIOT, Chef de...

HUDERF and ULB
" Role of Children in Sars-Cov-2 transmission, Heath Care Worker protection, Paediatric epidemiology and disease burden "
Funding: FNRS funding under assessment.
Contact: Prof Pierre Smeesters Academic Children Hospital Queen Fabiola Molecular Bacteriology Laboratory, ULB This email address is being protected from spambots. You need JavaScript enabled to view it.

ULB, Hôpital Erasme - FNRS
Lung injury, endothelial dysfunction and the role of RAAS during SARS-CoV-2 invection. " The first case of a person infected with SARS-Cov-2 virus can be tracked back on November the 17th, 2019, in China. On March 11, 2020, the World Health Organization (WHO) declared COVID-19 outbreak a pandemic. On April 13, COVID-19 is affecting 210 countries and territories worldwide, about 2 million positive cases have been officially declared along with 115.000 deaths. The real number of infected and deaths is scarily higher, considering that up to 65% people are asymptomatic and thus, not tested. The percentage of patients with COVID-19 needed for intensive care unit (ICU) varied from 5 to 32% in Wuhan, China. It was up to 9% in Lombardy, Italy. According to available data from Lombardy, 99% of patients admitted to the ICU needed respiratory support (88% invasive ventilation, 11% non invasive ventilation). In this unprecedented time, while SARS-Cov-2 virus is halting...

Read more: Sofia Morra, FNRS Research Fellow

UMONS and Ambroise-Paré Hospital Mons
" Predictive plasma signature of the clinical behavior of COVID-19 patients. The clinical presentation of COVID-19 infection varies from mild to asymptomatic to pneumonia, which can be complicated by severe respiratory failure and/or cardiovascular, renal, hepatic and cutaneous involvement. The understanding of such a polymorphism is very incomplete and the prognosis is difficult. Several tracks involving inflammatory reactions are currently favored to better explain this disease. In particular, the significant increase in plasma cytokines IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A and TNFα, known as "cytokine storm", seems to be significantly associated with the ARDS and multi-organ onsets. In this context, IL6 seems to play an important role and targeted treatments against this cytokine seem promising. Also, the infection of endothelial cells by the coronavirus causing endothelium inflammation have been suggested as one of the fundamental...

Read more: Stéphane CARLIER, Prof - Jean-Marie COLET, Prof - Fabrice JOURNE, Dr - Sven SAUSSEZ, Prof- Vincent...

Uliège & CHU of Liège - Royal Academy of Medicine of Belgium
" This is a phase 1-2 clinical trial entitled "Mesenchymal stromal cell therapy for severe COVID-19 infection" exploring the safety and preliminary efficacy of treatment with mesenchymal stromal cells in patients with severe COVID-19 infection. "
Funding: CHU of Liège
Contact: Céline Grégoire, Dpt of Hematology M Moutschen, Dpt of Microbiology B Misset, Dpt of Intensive Care C Lechanteur, Lab of Cell Therapy CHU of Liège